Abstract: Introduction: methotrexate in weekly low dose pulse of 7.5 mg has long proved its efficacy in the treatment of ocular lesions. During the 1998 ACR congress where we presented our data on 262 patients it was suggested the high dose of 15 mg. This is the short-term result of that study. Materials and Methods: MTX was used as 15 mg weekly. Prednisolone was associated as 0.5 mg/kg/ daily. The visual ...
ORIGIN AND OUTCOME OF MACULAR EDEMA IN OCULAR-BEHCET.
Abstract: The chronic macular edema, frequent in ocular Behcet's disease, is a treat to the visual outcome of the patients. We have investigated the origin, risk-factors and the outcome of macular edema in patents under immunosuppressors and corticosteroid therapy. This is a retrospective, case series study. In 1999,seventeen patients of the Behcet's clinic of Shariati hospital of Tehran who had macular edema were consecutively selected and included in the study. They were ...
The Impact of the Treatment Delay on the Outcome of Vision in Ocular Lesions of Behcet's Disease.
Abstract: Introduction: Ocular lesions of Behcet’s disease (BD) progress by recurrent attacks and remission. Their natural history, without treatment, is toward severe loss of vision or blindness. We presented last year a work to the ACR meeting on the long-term outcome of visual acuity (VA) in BD. The data showed that the final VA was related to the baseline VA (before the treatment), suggesting that a delay in aggressive treatment may ...
THE INFLUENCE OF PATHERGY TEST ON THE ACCURACY OF DIFFERENT DIAGNOSIS CRITERIA FOR BEHCET’S DISEASE.
Abstract: Introduction: Pathergy test (PAT) is used in the majority of diagnosis criteria set for Behcet’s Disease (BD). The modality of performing it (needle gauge, sharpness of the tip, direction of skin penetration, with or without a product injection), the delay to read the result (24 or 48 hours), and the cut-off line for positive test is not standardized. Therefore the results differ from one center to another, introducing a great ...
THE INFLUENCE OF SEX ON THE FREQUENCY OF CLINICAL SYMPTOMS IN BEHCET’S DISEASE.
Abstract: Introduction: It is known from long date that some manifestations are seen more frequently in men than women and in some of them the difference may be statistically significant. The aim of this study was to address that issue and to find if a statistical difference was of any clinical relevance or significance Materials and Methods: All patients of the BD registry (4717 at January 20, 2002) entered the ...
Clinical Manifestattion Of Behcet’s Disease.
Abstract: Objectives: Behcet's disease (BD) is a multi-system disease. We present here the various clinical aspects of BD based on the data of 4586 Iranian patients. The male to female ratio was 1.17/l. The mean age at the onset of the disease was 26 yr (SD:9.6, CI:0.3). The mean disease duration was 9 yr (SD:7), and the mean follow up time was 3 yr (SD:3.8). As the first manifestation of the ...
EXPERIENCE IN IRAN WITH SPECIAL REFERENCE TO BEHCETS DISEASE (BD).
Abstract: Pattern of Rheumatic Diseases in Iran: They have the same frequency and the same pattern as in Western countries. A study from 1993 demonstrated a prevalence of 32.6% among adults (31.4% in the USA, Cunningham 1984). Inflammatory disorders counted for 11% of all rheumatic diseases. The ratio of RA to AS was 8/1 (7/1 in USA), and SLE to Scleroderma 3.5/1 (3.6/1 in USA). Psoriatic arthritis and Reiter's syndrome were ...
THE ACCURACY OF IBDDAM (IRAN BEHCET'S DISEASE DYNAMIC ACTIVITY MEASURE) IN THE TREATMENT EVALUATION OF BEHCET'S DISEASE.
Abstract: Introduction: Behcet's Disease (BD) is characterized by recurrent attacks and remissions, making difficult the assessment of the treatment's result. Moreover, the remission period between the attacks is not the same and may vary from one attack to another. The attack periods are not always the same and may vary in severity, or extent of organ involvement. Iran Behcet's Disease Dynamic Activity Measure (IBDDAM) takes in account all of these parameters ...
LONG-TERM OUTCOME OF VISION IN BEHCET'S DISEASE.
Abstract: INTRODUCTION: The natural history of ocular lesions in Behcet's Disease (BD) is gradual progressions of lesions toward severe loss of vision or blindness. The association of cytotoxic drugs and steroids has dramatically changed the outcome. However, some authors still believe that the improvement is temporary and in the long run (10 years) the eyes progress toward blindness no matter what treatment was applied. The aim of this study was to ...
LONG-TERM OUTCOME OF VISION IN BEHCET’S DISEASE.
Abstract: INTRODUCTION: The natural history of ocular lesions Behcet’s Disease (BD) is gradual progressions of lesions toward severe loss of vision or blindness. The association of cytotoxic drugs and steroids has dramatically changed the outcome. However, some authors still believe that the improvement is temporary and in the long run (10 years) the eyes progress toward blindness no matter what treatment was applied. The aim of this study was to address ...